1.58

1.27% +0.01

Immuneering Corp (IMRX)

Overview News Price History Financials Discussions Forecast

Immuneering Corp stock is currently priced at $1.58, with a 24-hour trading volume of 11,416. It has seen a +1.27% increased in the last 24 hours and a -13.59% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $1.58 pivot point. If it approaches the $1.53 support level, significant changes may occur.

Previous Close:

$1.57

Open:

$1.56

24h Volume:

11,416

Market Cap:

$46.56M

Revenue:

$317.00K

Net Income/Loss:

$-53.47M

P/E Ratio:

-0.8187

EPS:

-1.93

Net Cash Flow:

$-49.31M

1W Performance:

+1.92%

1M Performance:

-13.59%

6M Performance:

-69.07%

1Y Performance:

-81.09%

1D Range:

$1.56

$1.6384

52W Range:

$1.38

$11.92

Immuneering Corp Stock (IMRX) Company Profile

Name

Immuneering Corp

Sector

Healthcare (1211)

Industry

Biotechnology (699)

Phone

617-500-8080

Address

245 Main Street, 2nd Floor, Cambridge

Employee

Twitter

Next Earnings Date

Latest SEC Filings

IMRX's Discussions on Twitter

Immuneering Corp Stock (IMRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-19-23	Upgrade	Mizuho	Neutral → Buy
Apr-19-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Mar-30-23	Initiated	Mizuho	Neutral
Feb-03-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Jul-08-22	Initiated	Chardan Capital Markets	Buy
Apr-01-22	Initiated	Oppenheimer	Outperform
Jan-07-22	Initiated	Piper Sandler	Overweight

View All

Immuneering Corp Stock (IMRX) Latest News

Immuneering Recognizes Melanoma Awareness Month

GlobeNewswire Inc.

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

GlobeNewswire Inc.

Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire Inc.

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

GlobeNewswire Inc.

Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Benzinga

Immuneering (IMRX) Plummets 71% in One Week: Here's Why

Zacks Investment Research

Immuneering Corp Stock (IMRX) Financials Data

Immuneering Corp (IMRX) Revenue 2024

IMRX reported a revenue (TTM) of $317.00 thousand for the quarter ending December 31, 2022, a -84.76% decline year-over-year.

Immuneering Corp (IMRX) Net Income 2024

IMRX net income (TTM) was -$53.47 million for the quarter ending December 31, 2023, a -5.86% decrease year-over-year.

Immuneering Corp (IMRX) Cash Flow 2024

IMRX recorded a free cash flow (TTM) of -$49.31 million for the quarter ending December 31, 2023, a -9.96% decrease year-over-year.

Immuneering Corp (IMRX) Earnings per Share 2024

IMRX earnings per share (TTM) was -$1.89 for the quarter ending December 31, 2023, a +1.56% growth year-over-year.

Immuneering Corporation is a biopharmaceutical company with a pipeline focusing on improving patient outcomes across a spectrum of oncologic and neurologic diseases by applying its bioinformatics to every stage of the drug development process. It provides bioinformatics and generates insights into drug mechanisms of action and patient treatment responses. The company was incorporated in 2008 and is based in Cambridge, Massachusetts.